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Abstract 
Background: The mortality of metabolic-obesity phenotypes has been thoroughly studied, but it is not known if or 
how the association between mortality and body mass index (BMI), waist circumference or a body shape index (ABSI) 
differ in strata of cardiometabolic health status.
Methods: We linked data on 12,815 men and women aged 36–79 years from the SAMINOR 1 Survey with mortality 
data from the Norwegian Cause of Death Registry. We defined metabolically healthy and unhealthy as having zero 
and ≥ 1, respectively, of the following: MetS, pre-existing diabetes or cardiovascular disease (CVD), or prescribed drugs 
for high blood pressure, hyperglycaemia or dyslipidaemia. We defined general and abdominal obesity as BMI ≥ 30 kg/
m2 and waist circumference ≥ 88 cm (women) or 102 cm (men), respectively, and cross-classified these categories 
with metabolic status to create metabolically healthy non-obese and obese (MHNO and MHO) and metabolically 
unhealthy non-obese and obese (MUNO and MUO) phenotypes. We used Cox regression to estimate the hazard ratio 
(HR) for all-cause and CVD mortality for 1) the four phenotypes and 2) BMI, waist circumference and ABSI fitted with 
restricted cubic splines. We adjusted for age and lifestyle, and tested for interactions with sex and metabolic status 
(only continuous measures).
Results: The MHO phenotype was present in 7.8% of women and 5.8% of men. During a median follow-up of 
15.3/15.2 years, 596/938 women/men had died, respectively. The MUNO and MUO groups had higher mortality than 
the MHNO group. Sex and phenotypes interacted with respect to CVD mortality: relative to the MHNO group, the 
MHO group had an adjusted HR (95% confidence interval) for CVD mortality of 1.05 (0.38–2.88) in women and 2.92 
(1.71–5.01) in men. We found curvilinear associations between BMI/waist circumference and all-cause mortality irre-
spective of metabolic status. Corresponding relationships with CVD mortality were linear and the slope differed by sex 
and metabolic status. ABSI was linearly and positively associated with all-cause and CVD mortality in men.
Conclusion: The relationships between BMI, waist circumference or ABSI and mortality differed by sex, metabolic 
status and cause of death. Poor metabolic health substantially increases mortality regardless of obesity status.
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Background
The prevalence of obesity doubled between 1980 and 
2015 in more than 70 countries [1]. Obesity is a strong 
driver of a cluster of risk factors known as metabolic 
syndrome (MetS). MetS is etiologically linked to insu-
lin resistance and visceral adipose tissue that promotes 
a proinflammatory and prothrombotic state, making it 
an antecedent of both cardiovascular disease (CVD) and 
type 2 diabetes mellitus [2]. At least half of the cardiovas-
cular risk linked to obesity is mediated through metabolic 
risk factors [3, 4]. In Europe, approximately 7–19% of 
people with obesity do not have MetS, so-called metabol-
ically healthy obesity (MHO) [5]. Accumulating evidence 
strongly suggests that, compared to the metabolically 
healthy normal-weight group, people with MHO are at 
increased risk of CVD [6–8], type 2 diabetes mellitus [9, 
10], and mortality [11, 12].
A body mass index (BMI) ≥ 30  kg/m2 is commonly 
used to define obesity in populations of European ances-
try, but BMI is a crude marker of body fat distribution. 
Waist circumference is a better measure of the visceral 
adipose tissue that is particularly strongly associated with 
cardiometabolic disease [13]. BMI and waist circumfer-
ence usually show J- or U-shaped associations with mor-
tality [14, 15]. This may indicate a functional relationship 
not reflected well by crude dichotomies, as dichotomisa-
tion of continuous predictors cause loss of information 
and statistical power to demonstrate associations [16]. 
However, BMI and waist circumference are usually highly 
correlated. Krakauer et al. developed a body shape index 
(ABSI), which is a measure of central obesity that has a 
low correlation with BMI [17].
To the best of our knowledge, no studies have exam-
ined the relationships between continuous measures 
of BMI, waist circumference or ABSI and mortality by 
metabolic health status. We aimed to examine these rela-
tionships using a population-based multi-ethnic sample 
of adult women and men from rural Northern Norway, 
which has high prevalence of both general and abdominal 
obesity and MetS [18, 19].
Methods
Data
We used the national 11-digit personal identity number 
linking individual data from the three following sources: 
baseline information on participants in the SAMINOR 
1 Survey (the first survey of the Population-based Study 
on Health and Living Conditions in Regions with Sami 
and Norwegian Populations—the SAMINOR Study), 
mortality data from the Norwegian Cause of Death 
Registry, and information on emigration from Statistics 
Norway.
The population of Northern Norway includes people 
of Norwegian, Sami and Kven (descendants of Finnish 
immigrants in the 18th and 19th Century) ethnicity. 
The Sami is an ethnic minority and acknowledged as 
an indigenous people. Traditionally, the Sami inhabited 
Northern parts of Norway, Sweden, Finland and the 
Kola Peninsula in the Russian Federation.
The SAMINOR Study is a population-based study 
designed to investigate the health and living condi-
tions in regions of Norway with an assumed propor-
tion of at least 5–10% Sami inhabitants. The Centre for 
Sami Health Research at UiT The Arctic University of 
Norway and the Norwegian Institute of Public Health 
conducted the SAMINOR 1 Survey in 2003–2004 in 
24 rural municipalities mainly in northern parts of 
Norway. Clinical measurements, blood samples and 
self-administered questionnaire data were collected on 
men and women aged 36–79  years. Of 27,151 invited 
individuals, 16,455 (60.6%) participated and consented 
to have their data linked to medical and national regis-
tries. Survey details have been reported previously [20].
Clinical measurements
The following measurements of each participant were 
made by trained personnel: waist circumference, 
recorded to the nearest centimetre at the umbilicus, 
the participant standing and breathing normally; height 
and weight, measured to the nearest 0.1  cm and 100  g, 
respectively, using an electronic scale with participants 
wearing light clothing and no shoes; and blood pres-
sure, measured with a Dinamap‐R automatic device 
(Critikon, Tampa, Florida, USA). Blood pressure was 
measured after a 2‐minute seated rest, and three meas-
urements with 1‐minute intervals were recorded. The 
first measurement was discarded and the average of the 
second and third was used. Trained personnel performed 
venepuncture with the participant in a seated position 
and non-fasting blood samples were centrifuged within 
1.5 h. Serum was sent by overnight post to the laboratory 
at Ullevål University Hospital, Oslo. Lipids and glucose 
were measured by an enzymatic method (Hitachi 917 
autoanalyzer, Roche Diagnostic, Switzerland).
Keywords: Abdominal obesity, A body shape index, All-cause mortality, Body mass index, Cardiovascular mortality, 
Metabolically healthy obesity, Metabolic syndrome, Obesity, Waist circumference
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Lifestyle and disease variables
Participants were asked to fill in a questionnaire from 
which we obtained the following information (answer 
options in parenthesis): education (total number of 
school years); diabetes (yes/no); angina pectoris (yes/
no); previous stroke (yes/no); previous heart attack 
(yes/no); use of blood pressure-lowering drug (cur-
rently/previously, but not now/never); use of cho-
lesterol‐lowering drug (currently/previously, but not 
now/never); use of insulin (currently/previously, but 
not now/never); use of glucose‐lowering drug in tab-
let format (currently/previously, but not now/never); 
smoking (currently/previously/never); alcohol con-
sumption (never/not this year/a few times during this 
year/1 time per month/2–3 times per month/1 time per 
week/2–3 times per week/4‐7 times per week). Alcohol 
consumption was categorised into “weekly alcohol con-
sumption”, “less than weekly alcohol consumption” and 
“never/not last year”. Leisure‐time physical activity was 
measured by a self-reported modified Saltin-Grimby 
Physical Activity Level scale (reading, watching televi-
sion, or engaging in sedentary activities/at least 4  h a 
week of walking, bicycling, or other types of physi-
cal activity/at least 4  h a week of participating in rec-
reational athletics or heavy gardening/regular, vigorous 
training or participating in competitive sports several 
times a week) [21]. The Saltin-Grimby Physical Activity 
Level scale has been used in many Nordic populations 
and has shown acceptable validity regarding objectively 
measured physical activity [21]. Leisure-time physi-
cal activity was categorised into “sedentary” (the first 
option), “light” (the second option) and “moderate-
hard” (the last two options merged). Participants were 
also asked to list any medication they had used within 
the last four weeks and the information was combined 
with information from drug-specific questions, details 
are found elsewhere [22].
The questionnaire also included questions (11 in total) 
on use of language at home by grandparents, parents and 
participants, ethnic background for parents and partici-
pants, and the participants’ self‐perceived ethnicity (one 
or more of these alternatives were allowed: Norwegian, 
Sami, Kven, and other). Participants were categorised as 
Sami if they answered Sami as (1) their self-perceived 
ethnicity or (2) their own ethnic background. All others 
were categorised as non-Sami.
Independent variables
We defined MetS according to the ‘harmonised’ Adult 
Treatment Panel-III definition, with some adaptations 
[23]. At least three of the following five components had 
to be present:
hypertension, defined as systolic blood pres-
sure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg 
or current use of antihypertensive drug;
elevated random glucose, defined as random serum 
glucose ≥ 7.8 mmol/L or self-reported diabetes;
increased waist circumference, defined as waist cir-
cumference ≥ 80 cm in women and ≥ 94 cm in men;
hypertriglyceridemia, defined as random serum triglyc-
erides ≥ 1.7 mmol/L; and
lowered HDL cholesterol, defined as random 
serum HDL cholesterol < 1.3  mmol/L in women 
and < 1.0 mmol/L in men.
Participants were categorised as metabolically 
unhealthy if they had any of the following, as recom-
mended by Smith et al. [24]:
MetS (for abdominal obesity phenotypes, the MetS 
definition was modified to the presence of any given 
two or more components excluding increased waist 
circumference);
self-reported diabetes, stroke, angina pectoris, or myo-
cardial infarction;
self-reported current treatment for high blood pres-
sure, hyperglycaemia or dyslipidaemia.
General and abdominal obesity were defined as 
BMI ≥ 30  kg/m2 and waist circumference ≥ 88  cm in 
women and ≥ 102 cm in men, respectively. The following 
general obesity phenotypes were created: metabolically 
healthy non-obesity (MHNO); metabolically unhealthy 
non-obesity (MUNO); metabolically healthy obesity 
(MHO); and metabolically unhealthy obesity (MUO). 
The following abdominal obesity phenotypes were cre-
ated: metabolically healthy non-abdominal-obesity 
(MHNAO); metabolically unhealthy non-abdominal-
obesity (MUNAO); metabolically healthy abdominal obe-
sity (MHAO); and metabolically unhealthy abdominal 
obesity (MUAO).
In addition to using BMI and waist circumference to 
define general and abdominal obesity, respectively, we 
also used them as continuous variables (BMI in kg/m2 
and waist circumference in cm). Due to the high cor-
relation between BMI and waist circumference (0.88 in 
women and 0.86 in men in this cohort), we also applied 
ABSI as developed by Krakauer et  al. based on a U.S. 
population-based cohort (NHANES) [17]:
The ABSI was transformed to a Z-score for interpret-
ability by subtracting the sex-specific mean and dividing 
by the sex-specific standard deviation. ABSI was not used 
as a determinant of categorical obesity because of the 
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Outcome variables
Mortality data comprised date of death and underlying 
cause of death, coded using the International Statistical 
Classification of Diseases and Related Health Problems, 
 10th revision. The study period started at the date of study 
entry (between 14th January 2003 and 5th March 2004) 
and ended at date of death (the event), date of emigration 
(censored) or the end of follow-up 31st December 2018 
(censored), whichever occurred first. The outcome vari-
ables of interest were all-cause mortality and CVD mor-
tality (death from causes I00-I99).
Missing data and exclusions
Figure 1 shows a flow chart describing the cohort selec-
tion. We excluded 497 participants who died within 
the first 5 years of follow-up and 90 participants with a 
BMI ≤ 18.5 kg/m2 to avoid the potential for reverse cau-
sality [14]. Because information on pre-existing disease 
or prescribed drugs was not necessary for the categori-
sation, we did not exclude participants with missing data 
for these variables. However, most participants with 
missing data for these variables were categorised into a 
metabolically unhealthy group by other determinants 
(Table  1). After exclusions, the complete case analyti-
cal sample comprised 12,815 participants, 47.2% of the 
invited sample.
Statistical analysis
Sample characteristics were described in strata of sex and 
metabolic–obesity phenotype and reported as mean (SD) 
and frequency (percentage) as appropriate. One-way 
analysis of variance and Pearson’s χ2 test were used to 
compare characteristics across the phenotypes. We cal-
culated age-standardised mortality rates using the direct 
method and the 2013 European standard population.
In separate models for each pair of outcome and expo-
sure, we modelled the relationships between all-cause 
mortality and CVD mortality (outcomes) and MetS, 
general obesity phenotypes and abdominal obesity phe-
notypes (exposures) using Cox proportional hazard 
regression. We tested interactions between exposures 
and sex, and between exposures and ethnicity, and com-
pared models with and without interaction terms using 
the likelihood ratio test. Interaction was considered 
present if p < 0.05. There were no significant interac-
tions with ethnicity, but we found evidence of interac-
tions between sex and general (p = 0.02) and abdominal 
(p = 0.05) obesity phenotypes for CVD mortality. There-
fore, all models were stratified by sex. Attained age was 
set as the time-scale as recommended in observational 
studies [25], hence, all models were inherently and non-
parametrically controlled for age (model 1). Further 
adjustments were made for smoking (model 2), plus lei-
sure-time physical activity, education and alcohol con-
sumption (model 3). Sami ethnicity is primarily regarded 
a sociocultural category in this cohort, and neither inter-
acted with nor affected the beta coefficient for the expo-
sures in the models, and was therefore not included in 
the models. The proportional hazard assumption was 
evaluated using Schoenfeld residuals. In models with all-
cause mortality, non-proportional hazards for smoking 
status were handled by allowing separate baseline haz-
ards for subgroups of the data, i.e. stratified Cox mod-
els. We reported adjusted hazard ratios (HR) with 95% 
confidence intervals (CI) for each pair of outcome and 
exposure.
Next, in separate models, we fitted BMI, waist cir-
cumference and ABSI as continuous variables using 
restricted cubic splines against all-cause and CVD mor-
tality, respectively, while adjusting for the same covari-
ates as in model 3 above, in addition to metabolic health. 
Fitting three knots provided the lowest Akaike informa-
tion criterion and were thus sufficient, as recommended 
by Harrell [26]. We assessed non-linearity by testing 
models with the linear term against models with both 
linear and a cubic spline term using likelihood ratio test. 
Non-linearity was considered present if p < 0.05. We also 
assessed interaction between metabolic health status and 
BMI/waist circumference/ABSI using likelihood ratio 
tests. If there was a significant interaction, we kept the 
Fig. 1 Flow-chart describing cohort selection from SAMINOR 1 
participants and patterns of missing data
Page 5 of 15Michalsen et al. BMC Cardiovasc Disord          (2021) 21:510  
Table.1 Sample characteristics in mean (standard deviation) or frequency (percent) according to general obesity phenotypes in 6517 
women in the SAMINOR 1 Survey (2003–2004)
Continuous variables are reported as mean (standard deviation) and categorical variables are given as frequency (percent). In the final sample, missing data existed 








(N = 1662, 25.5%)
Metabolically healthy 




(N = 1250, 19.2%)
Total (N = 6517) p value
Age (years) 49.4 (9.4) 57.4 (10.7) 52.1 (10.2) 57.4 (11.0) 53.2 (10.8)  < 0.0011
Ethnicity  < 0.0012
non-Sami 2462 (79.5%) 1319 (79.4%) 349 (68.4%) 920 (73.6%) 5050 (77.5%)
Sami 633 (20.5%) 343 (20.6%) 161 (31.6%) 330 (26.4%) 1467 (22.5%)
Smoking  < 0.0012
Yes, currently 1063 (34.3%) 588 (35.4%) 120 (23.5%) 277 (22.2%) 2048 (31.4%)
Yes, previously 948 (30.6%) 481 (28.9%) 192 (37.6%) 441 (35.3%) 2062 (31.6%)
Never 1084 (35.0%) 593 (35.7%) 198 (38.8%) 532 (42.6%) 2407 (36.9%)
Died during follow-up 154 (5.0%) 230 (13.8%) 25 (4.9%) 187 (15.0%) 596 (9.1%)  < 0.0012
Cause of death  < 0.0012
Malignant tumor 83 (53.9%) 63 (27.4%) 12 (48.0%) 60 (32.1%) 218 (36.6%)
CVD 16 (10.4%) 73 (31.7%) 5 (20.0%) 58 (31.0%) 152 (25.5%)
Respiratory 19 (12.3%) 25 (10.9%) 3 (12.0%) 15 (8.0%) 62 (10.4%)
Other 33 (21.4%) 67 (29.1%) 4 (16.0%) 51 (27.3%) 155 (26.0%)
Unknown 3 (1.9%) 2 (0.9%) 1 (4.0%) 3 (1.6%) 9 (1.5%)
Alcohol consumption  < 0.0012
Weekly 822 (26.6%) 296 (17.8%) 89 (17.5%) 132 (10.6%) 1339 (20.5%)
Less than weekly 1881 (60.8%) 958 (57.6%) 312 (61.2%) 741 (59.3%) 3892 (59.7%)
Never/not last year 392 (12.7%) 408 (24.5%) 109 (21.4%) 377 (30.2%) 1286 (19.7%)
Leisure-time physical activity  < 0.0012
Sedentary 594 (19.2%) 394 (23.7%) 140 (27.5%) 397 (31.8%) 1525 (23.4%)
Light 2082 (67.3%) 1100 (66.2%) 324 (63.5%) 751 (60.1%) 4257 (65.3%)
Moderate-hard 419 (13.5%) 168 (10.1%) 46 (9.0%) 102 (8.2%) 735 (11.3%)
Education (years) 12.6 (3.9) 10.6 (3.7) 11.6 (4.1) 10.5 (3.9) 11.6 (4.0)  < 0.0011
General obesity 0 (0.0%) 0 (0.0%) 510 (100.0%) 1250 (100.0%) 1760 (27.0%)
Metabolic syndrome 0 (0.0%) 948 (57.0%) 0 (0.0%) 990 (79.2%) 1938 (29.7%)  < 0.0012
Hypertension 802 (25.9%) 1173 (70.6%) 176 (34.5%) 1023 (81.8%) 3174 (48.7%)  < 0.0012
Increased waist circumference 1274 (41.2%) 1267 (76.2%) 503 (98.6%) 1244 (99.5%) 4288 (65.8%)  < 0.0012
Low HDL cholesterol 542 (17.5%) 768 (46.2%) 102 (20.0%) 768 (61.4%) 2180 (33.5%)  < 0.0012
Elevated triglycerides 308 (10.0%) 810 (48.7%) 59 (11.6%) 792 (63.4%) 1969 (30.2%)  < 0.0012
Hyperglycemia 30 (1.0%) 157 (9.4%) 2 (0.4%) 194 (15.5%) 383 (5.9%)  < 0.0012
Stroke 0 (0.0%) 68 (4.5%) 0 (0.0%) 37 (3.2%) 105 (1.7%)  < 0.0012
Missing data 3 166 2 83 254
Angina pectoris 0 (0.0%) 146 (9.8%) 0 (0.0%) 134 (11.4%) 280 (4.5%)  < 0.0012
Missing data 3 167 2 73 245
Myocardial infarction 0 (0.0%) 58 (3.9%) 0 (0.0%) 36 (3.1%) 94 (1.5%)  < 0.0012
Missing data 3 165 2 80 250
Diabetes 0 (0.0%) 101 (6.7%) 0 (0.0%) 133 (11.3%) 234 (3.7%)  < 0.0012
Missing data 3 163 2 74 242
Blood pressure-lowering drug 0 (0.0%) 713 (43.8%) 0 (0.0%) 629 (50.9%) 1342 (20.8%)  < 0.0012
Missing data 3 36 2 14 55
Cholesterol-lowering drug 0 (0.0%) 460 (29.0%) 0 (0.0%) 303 (25.5%) 763 (12.0%)  < 0.0012
Missing data 3 75 2 60 140
Glucose-lowering drug 0 (0.0%) 96 (6.3%) 0 (0.0%) 108 (9.3%) 204 (3.2%)  < 0.0012
Missing data 3 136 2 93 234
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interaction term in the model; if there was no interac-
tion, metabolic health status was kept in the model as a 
covariate. Adjusted HR (95% CI) of all-cause and CVD 
mortality, respectively, were plotted against BMI, waist 
circumference and ABSI, respectively, with separate 
curves for metabolically healthy and unhealthy, using the 
sex-specific sample median of BMI, waist circumference 
or ABSI as reference values. In models with a significant 
interaction, metabolically healthy with the sex-specific 
sample median of BMI, waist circumference or ABSI 
were used as reference.
We used R version 3.6.2 for Windows for statistical 
computing [27]. Code and output is found in the Addi-
tional file 1
Sensitivity analysis
We excluded (1) ever-smokers and (2) participants with 
pre-existing diseases (or prescribed drugs for cardio-
metabolic disease) in sensitivity analyses. Furthermore, 
we analysed data with more conservative cut-offs for 
MetS-components: waist circumference (≥ 88/102  cm 
in women/men), random triglycerides (≥ 2.1  mmol/L), 
and random glucose (≥ 11.1 mmol/L). We also repeated 
the analyses in the full sample, adjusting for sex. Finally, 
we used multiple imputation to address missing data on 
at least one variable for 2030 participants (13.7%). The 
variables with the largest proportion of missing data 
were found for leisure-time physical activity (n = 1322, 
8.9%) and education (n = 881, 5.9%). Characteristics dif-
fered between participants with complete and missing 
data (Additional file  1: Table  S1). The mechanism for 
missing information was assumed to be missing-at-ran-
dom [28]. We used a rich set of relevant variables, per-
formed 20 imputations, and pooled the data according to 
Rubin’s rules using the ‘mice’ package in R [29]. Because 
metabolic health is a known mediator of the relationship 
between obesity and mortality, we also ran the analyses 
of continuous BMI/waist circumference/ABSI vs mortal-
ity without adjusting for metabolic health.
Results
After median follow-up of 15.3 years in 6517 women and 
15.2 years in 6298 men (12,815 in total), 596 (9.1%) and 
938 (14.9%) had died, respectively. In both women and 
men, the prevalence of MetS was 29.7%. Proportions 
categorised as metabolically unhealthy (defined as either 
having MetS, pre-existing disease or prescribed drugs) 
were 44.7% in women and 47.0% in men. Proportions 
having general obesity were 27.0% in women and 23.5% 
in men, and proportions having abdominal obesity were 
39.0% in women and 21.1% in men.
Tables 1 and 2 describe the prevalence of the four gen-
eral obesity phenotypes and the distributions of char-
acteristics across the phenotypes in women and men, 
respectively. Compared to the other groups, men and 
women with MHO were relatively young, with a higher 
proportion of people with Sami ethnicity, a lower propor-
tion of current smokers, and a higher proportion of peo-
ple who reported being sedentary in their leisure-time 
(but lower than in people with MUO). Additional file 1: 
Tables S2 and S3 describe the distribution and character-
istics of the four abdominal obesity phenotypes. Patterns 
of characteristics were generally similar to those reported 
for general obesity phenotypes.
The proportion of deaths during follow-up were com-
parable in people with MHO and people with MHNO, 
but they differed in the distribution of causes of death 
(Tables 1 and 2). In general, the proportion of death from 
CVD was lowest in the MHNO group.
Figure  2 shows that the lowest mean mortality rates 
in men occurred in the MHNO and MHNAO groups, 
whereas in women, the metabolically healthy phenotypes 
regardless of obesity status had the lowest mortality rates.
Tables 3 and 4 show the hazard ratios (HR) from Cox 
proportional hazards models for all-cause mortality and 
CVD mortality in women and men, respectively. Men 
and women with MetS had an approximately 50% higher 
15-year risk of CVD mortality than those without MetS. 
The 15-year mortality in the subgroups with MHO and 
MHAO compared to the respective metabolically healthy 
non-obese groups differed markedly between the sexes, 
particularly for CVD mortality, with significant interac-
tions with sex differences in the beta coefficient for MHO 
and MHAO primarily. We found that obesity, regardless 
of metabolic health, markedly increased CVD mortality 
in men, but there was no association in women. In the 
metabolically healthy, all-cause mortality was reduced in 
obese women (general and abdominal, respectively) com-
pared to non-obese women. In both sexes, the mortality 
associated with metabolically unhealthy obesity pheno-
types (MUNO, MUNAO, MUO, MUAO) were higher for 
CVD-specific death than for all-cause mortality.
Figures 3 and 4 (panels A and C) show curvilinear rela-
tionships between all-cause mortality and BMI (panel A) 
table. It is evident that most people with missing nevertheless was categorised in an unhealthy group
HDL = high-density lipoprotein, CVD = cardiovascular disease
1 One way analysis of variance
2 Pearson’s χ2 test
Table.1 (continued)
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Table.2 Sample characteristics in mean (standard deviation) or frequency (percent) according to general obesity phenotypes in 6298 








(N = 1843, 29.2%)
Metabolically healthy 




(N = 1120, 17.8%)
Total (N = 6298) p-value
Age (years) 51.4 (9.9) 57.8 (10.8) 51.3 (10.1) 55.4 (10.3) 54.0 (10.6)  < 0.0011
Ethnicity 0.0022
non-Sami 2264 (76.2%) 1452 (78.8%) 253 (69.7%) 865 (77.2%) 4834 (76.8%)
Sami 708 (23.8%) 391 (21.2%) 110 (30.3%) 255 (22.8%) 1464 (23.2%)
Smoking  < 0.0012
Yes, currently 1060 (35.7%) 549 (29.8%) 86 (23.7%) 260 (23.2%) 1955 (31.0%)
Yes, previously 982 (33.0%) 830 (45.0%) 158 (43.5%) 571 (51.0%) 2541 (40.3%)
Never 930 (31.3%) 464 (25.2%) 119 (32.8%) 289 (25.8%) 1802 (28.6%)
Died during follow-up 297 (10.0%) 402 (21.8%) 39 (10.7%) 200 (17.9%) 938 (14.9%)  < 0.0012
Cause of death  < 0.0012
Malignant tumor 124 (41.8%) 123 (30.6%) 12 (30.8%) 63 (31.5%) 322 (34.3%)
CVD 56 (18.9%) 135 (33.6%) 18 (46.2%) 75 (37.5%) 284 (30.3%)
Respiratory 38 (12.8%) 47 (11.7%) 5 (12.8%) 14 (7.0%) 104 (11.1%)
Other 75 (25.3%) 91 (22.6%) 3 (7.7%) 41 (20.5%) 210 (22.4%)
Unknown 4 (1.3%) 6 (1.5%) 1 (2.6%) 7 (3.5%) 18 (1.9%)
Alcohol consumption  < 0.0012
Weekly 1046 (35.2%) 545 (29.6%) 117 (32.2%) 315 (28.1%) 2023 (32.1%)
Less than weekly 1691 (56.9%) 1057 (57.4%) 213 (58.7%) 683 (61.0%) 3644 (57.9%)




Sedentary 602 (20.3%) 417 (22.6%) 93 (25.6%) 339 (30.3%) 1451 (23.0%)
Light 1571 (52.9%) 1088 (59.0%) 200 (55.1%) 616 (55.0%) 3475 (55.2%)
Moderate-hard 799 (26.9%) 338 (18.3%) 70 (19.3%) 165 (14.7%) 1372 (21.8%)
Education (years) 11.7 (3.8) 10.6 (3.7) 11.2 (3.4) 10.8 (3.7) 11.2 (3.8)  < 0.0011
General obesity 0 (0.0%) 0 (0.0%) 363 (100.0%) 1120 (100.0%) 1483 (23.5%)
Metabolic syndrome 0 (0.0%) 970 (52.6%) 0 (0.0%) 900 (80.4%) 1870 (29.7%)  < 0.0012
Hypertension 1271 (42.8%) 1493 (81.0%) 164 (45.2%) 972 (86.8%) 3900 (61.9%)  < 0.0012
Increased waist cir-
cumference
636 (21.4%) 1031 (55.9%) 331 (91.2%) 1097 (97.9%) 3095 (49.1%)  < 0.0012
Low HDL cholesterol 258 (8.7%) 592 (32.1%) 22 (6.1%) 488 (43.6%) 1360 (21.6%)  < 0.0012
Elevated triglycerides 825 (27.8%) 1040 (56.4%) 93 (25.6%) 815 (72.8%) 2773 (44.0%)  < 0.0012
Hyperglycemia 44 (1.5%) 230 (12.5%) 3 (0.8%) 163 (14.6%) 440 (7.0%)  < 0.0012
Stroke 0 (0.0%) 100 (5.9%) 0 (0.0%) 51 (4.8%) 151 (2.5%)  < 0.0012
Missing data 6 145 0 52 203
Angina pectoris 0 (0.0%) 318 (18.6%) 0 (0.0%) 138 (12.9%) 456 (7.5%)  < 0.0012
Missing data 6 137 0 48 191
Myocardial infarction 0 (0.0%) 236 (13.7%) 0 (0.0%) 110 (10.2%) 346 (5.7%)  < 0.0012
Missing data 6 124 0 45 175
Diabetes 0 (0.0%) 135 (7.9%) 0 (0.0%) 85 (7.9%) 220 (3.6%)  < 0.0012
Missing data 6 134 0 45 185
Blood pressure-lower-
ing drug
0 (0.0%) 837 (46.4%) 0 (0.0%) 504 (45.4%) 1341 (21.5%)  < 0.0012
Missing data 6 38 0 10 54
Cholesterol-lowering 
drug
0 (0.0%) 630 (35.6%) 0 (0.0%) 320 (29.5%) 950 (15.4%)  < 0.0012
Missing data 6 74 0 35 115









(N = 1843, 29.2%)
Metabolically healthy 




(N = 1120, 17.8%)
Total (N = 6298) p-value
Glucose-lowering drug 0 (0.0%) 131 (7.7%) 0 (0.0%) 66 (6.3%) 197 (3.2%)  < 0.0012
Missing data 6 141 0 68 215
Continuous variables are reported as mean (standard deviation) and categorical variables are given as frequency (percent). In the final sample, missing data existed 
only in pre-existing disease and drug variables; in categorisation of metabolic health status, missing was assumed “no”, but frequencies of missing are shown in this 
table. It is evident that most people with missing nevertheless was categorised in an unhealthy group
HDL = high-density lipoprotein, CVD = cardiovascular disease
1 One way analysis of variance
2 Pearson’s χ2 test
Table.3 All-cause and CVD mortality according to MetS, general and abdominal obesity phenotypes: Hazard ratios (HR) and 95% 
confidence intervals (CI) from Cox proportional hazards models of 6517 women in the SAMINOR 1 Survey (2003–2004)
Model 1 is the crude model (all models inherently adjusted for age by using attained age as the time-scale). Model 2 was additionally adjusted for smoking, and model 
3 was additionally adjusted for leisure-time physical activity, education and alcohol consumption (model 3). We applied stratified Cox models with separate baseline 
hazards for subgroups of smoking status to satisfy the proportional hazard assumption in all-cause mortality models
IR = crude incidence rate per 1000 person-years, HR = hazard ratio, CI = confidence interval
Model 1 Model 2 Model 3
Cases Person-years IR HR 95% CI HR 95% CI HR 95% CI
Outcome: All-cause mortality
Metabolic syndrome
No 343 68,588.7 5.0 Ref Ref Ref
Yes 253 28,604.7 8.8 1.14 0.97–1.35 1.15 0.97–1.35 1.11 0.94–1.31
General obesity phenotypes
Metabolically healthy non-obese 154 46,629.4 3.3 Ref Ref Ref
Metabolically unhealthy non-obese 230 24,487.6 9.4 1.13 0.92–1.40 1.14 0.92–1.41 1.11 0.90–1.38
Metabolically healthy obese 25 7753.5 3.2 0.64 0.42–0.97 0.68 0.44–1.04 0.63 0.41–0.97
Metabolically unhealthy obese 187 18,322.8 10.2 1.17 0.94–1.46 1.27 1.02–1.59 1.17 0.93–1.47
Abdominal obesity phenotypes
Metabolically healthy non-abdominally obese 119 39,259.1 3.0 Ref Ref Ref
Metabolically unhealthy non-abdominally obese 170 20,308.6 8.4 1.12 0.88–1.43 1.14 0.89–1.45 1.12 0.88–1.43
Metabolically healthy abdominally obese 42 12,571.2 3.3 0.71 0.50–1.01 0.75 0.53–1.07 0.71 0.50–1.02
Metabolically unhealthy abdominally obese 265 25,054.5 10.6 1.23 0.99–1.55 1.31 1.04–1.64 1.22 0.97–1.54
Outcome: CVD mortality
Metabolic syndrome
No 73 68,588.7 1.1 Ref Ref Ref
Yes 79 28,604.7 2.8 1.55 1.12–2.13 1.53 1.11–2.11 1.46 1.06–2.02
General obesity phenotypes
Metabolically healthy non-obese 16 46,629.4 0.3 Ref Ref Ref
Metabolically unhealthy non-obese 73 24,487.6 3.0 2.86 1.65–4.95 2.88 1.66–4.99 2.77 1.59–4.80
Metabolically healthy obese 5 7753.5 0.6 1.08 0.40–2.96 1.12 0.41–3.07 1.05 0.38–2.88
Metabolically unhealthy obese 58 18,322.8 3.2 2.81 1.60–4.94 2.93 1.66–5.15 2.65 1.49–4.72
Abdominal obesity phenotypes
Metabolically healthy non-abdominally obese 16 39,259.1 0.4 Ref Ref Ref
Metabolically unhealthy non-abdominally obese 48 20,308.6 2.4 1.90 1.07–3.38 1.93 1.09–3.43 1.86 1.05–3.32
Metabolically healthy abdominally obese 5 12,571.2 0.4 0.55 0.20–1.50 0.57 0.21–1.56 0.54 0.20–1.47
Metabolically unhealthy abdominally obese 83 25,054.5 3.3 2.25 1.30–3.88 2.31 1.34–3.99 2.11 1.21–3.69
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and waist circumference (panel C) in women and men, 
respectively. Figures 3 and 4 (panels E) show curvilinear 
and linear relationships between all-cause mortality and 
ABSI in women and men, respectively. Figures  3 and 4 
(panels B, D and F) show marked sex-differences in the 
relationships with CVD mortality for BMI (panel B), 
waist circumference (panel D) and ABSI (panel F). Inter-
actions were present between metabolic health status 
and obesity measures in CVD models (except in panel 3B 
and 4F). In men, all obesity measures had positive, strong 
associations with CVD mortality. We found stronger 
associations (steeper slopes) in metabolically healthy 
than unhealthy groups in models with BMI and waist 
circumference, but not in models with ABSI. In women, 
BMI had negative associations with CVD mortality. The 
association between waist circumference or ABSI and 
CVD mortality differed by metabolic health status.
Sensitivity analysis
Additional file 1: Tables S4, S5 and S6 show the results of 
the sensitivity analyses. In never-smokers, most associa-
tions between general and abdominal obesity phenotypes 
and mortality were stronger than those observed in the 
whole cohort, but several estimates included 1.0 in the 
CI. Contrary, in participants without pre-existing disease 
or prescribed drugs, most estimates were strongly atten-
uated and not statistically significant (except men with 
MHO and MHAO) compared to those observed in the 
whole cohort. Using more conservative cut-offs for 
MetS resulted in increased estimates, and the apparent 
protective effect of MHO and MHAO in women was 
attenuated towards the null and was no longer statisti-
cally significant. In sex-adjusted analyses, HR (95%) for 
all-cause mortality compared to the reference groups 
were 0.92 (0.71–1.20) for MHO and 0.92 (0.72–1.17) 
for MHAO, respectively. Analysis of multiply imputed 
data gave similar results compared to the complete case 
analysis. Additional file 1: Figs. S1 and S2 of “unadjusted” 
obesity vs mortality models show overall patterns simi-
lar with the primary analyses. An exception was seen for 
models with CVD mortality in women (Figure S1), which 
showed no association with BMI  (panel B) or waist cir-
cumference (panel D), but a curvilinear association with 
ABSI (panel F) indicating significantly higher mortality at 
higher ends of the scale.
Discussion
We followed almost 13,000 adults for 15 years and found 
that metabolically unhealthy status was associated with 
a higher CVD mortality than metabolically healthy sta-
tus irrespective of obesity status. We found curvilinear 
associations between BMI (women and men), waist cir-
cumference (women and men) or ABSI (women) and 
all-cause mortality regardless of metabolic health status. 
However, in men, the relationship between ABSI and all-
cause mortality was linear. Corresponding relationships 
between these three continuous obesity measures and 
CVD mortality differed by both sex and metabolic health 
status. Ethnicity had no impact on the results.
To our knowledge, this study is the first to examine 
the relationship between continuous measures of BMI, 
waist circumference or ABSI and mortality according 
to metabolic health status. A recent study of a Japanese 
population by Izumida et al. examined the relationships 
between four categories of BMI and 18-year mortality 
according to MetS status [30]. The relationship between 
BMI categories and all-cause and CVD mortality were 
J-shaped in metabolically unhealthy people, whereas no 
associations were found in metabolically healthy peo-
ple. In contrast, we show that the relationships between 
BMI and CVD mortality in a Norwegian population 
differ by sex: with no or negative association in women 
and positive association in men. A meta-analysis of 
21 prospective studies showed that compared to the 
MHNO group, the HR for CVD in women with MHO 
were lower than those in men with MHO (HR 1.71 vs 
2.15, respectively) [31]. However, the meta-analysis 
included few sex-stratified studies. In a recent Iranian 
Fig. 2 Age-standardised mortality rates per 1000 person-years 
with 95% CI for all-cause and CVD mortality given by general and 
abdominal obesity phenotypes. MHNO = metabolically healthy 
non-obesity, MUNO = metabolically unhealthy non-obesity, 
MHO = metabolically healthy obesity, MUO = metabolically 
unhealthy obesity, MHNAO = metabolically healthy non-abdominal 
obesity, MUNAO = metabolically unhealthy non-abdominal 
obesity, MHAO = metabolically healthy abdominal obesity, 
MUAO = metabolically unhealthy abdominal obesity
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study, neither women nor men with persistent MHO 
status had increased HR for CVD incidence compared 
to the non-obese comparison group [32]. However, 
among women and men who transitioned from MHO 
to MUO, only men had an increased HR compared to 
the non-obese comparison group [32]. In the study by 
Izumida et al., the authors adjusted for sex, whereas we 
found an interaction, but only regarding CVD mortal-
ity. The association between BMI/waist circumference 
and all-cause mortality was U-shaped in both sexes. 
Although the HR of MHO for all-cause mortality dif-
fered by sex (HR of 0.63 in women and 1.25 in men), 
there was no evidence of statistically significant effect 
modification. In sensitivity analyses, the (sex-adjusted) 
HR (95% CI) of MHO was 0.92 (0.71–1.21).
The amount of visceral adipose tissue may differ 
between people with the same value of BMI or even waist 
circumference, and men typically have more visceral 
adipose tissue than women [13]. This may have contrib-
uted to the sex-differences in associations between obe-
sity measures and CVD mortality in women and men. A 
recent UK Biobank study including nearly 300,000 men 
and women without CVD at baseline showed that BMI 
had J-shaped associations with CVD events and mor-
tality in both sexes [33]. In men, the association with 
CVD events was linear when restricted to non-smokers. 
Residual confounding when adjusting for crude smoking 
Table.4 All-cause and CVD mortality according to MetS, general and abdominal obesity phenotypes: Hazard ratios (HR) and 95% 
confidence intervals (CI) from Cox proportional hazards models of 6298 men in SAMINOR 1 (2003–2004)
Model 1 is the crude model (all models inherently adjusted for age by using attained age as the time-scale). Model 2 was additionally adjusted for smoking, and model 
3 was additionally adjusted for leisure-time physical activity, education and alcohol consumption (model 3). We applied stratified Cox models with separate baseline 
hazards for subgroups of smoking status to satisfy the proportional hazard assumption in all-cause mortality models
IR = crude incidence rate per 1000 person-years, HR = hazard ratio, CI = confidence interval
Model 1 Model 2 Model 3
Cases Person-years IR HR 95% CI HR 95% CI HR 95% CI
Outcome: All-cause mortality
Metabolic syndrome
No 627 65,040.4 9.6 Ref Ref Ref
Yes 311 27,124.8 11.5 1.06 0.93–1.22 1.11 0.97–1.28 1.10 0.96–1.26
General obesity phenotypes
Metabolically healthy non-obese 297 44,234.7 6.7 Ref Ref Ref
Metabolically unhealthy non-obese 402 26,321.0 15.3 1.12 0.96–1.31 1.18 1.01–1.38 1.16 0.99–1.35
Metabolically healthy obese 39 5381.8 7.2 1.13 0.81–1.57 1.28 0.91–1.79 1.25 0.89–1.75
Metabolically unhealthy obese 200 16,227.8 12.3 1.22 1.02–1.46 1.38 1.14–1.65 1.33 1.11–1.61
Abdominal obesity phenotypes
Metabolically healthy non-abdominally obese 241 38,178.8 6.3 Ref Ref Ref
Metabolically unhealthy non-abdominally obese 430 34,896.0 12.3 1.13 0.97–1.33 1.20 1.02–1.41 1.18 1.00–1.38
Metabolically healthy abdominally obese 40 4344.3 9.2 1.12 0.80–1.57 1.23 0.88–1.73 1.20 0.86–1.69
Metabolically unhealthy abdominally obese 227 14,746.1 15.4 1.39 1.16–1.67 1.53 1.27–1.84 1.49 1.23–1.79
Outcome: CVD mortality
Metabolic syndrome
No 170 65,040.4 2.6 Ref Ref Ref
Yes 114 27,124.8 4.2 1.43 1.13–1.82 1.53 1.20–1.94 1.51 1.18–1.91
General obesity phenotypes
Metabolically healthy non-obese 56 44,234.7 1.3 Ref Ref Ref
Metabolically unhealthy non-obese 135 26,321.0 5.1 1.95 1.42–2.68 2.11 1.54–2.90 2.08 1.51–2.86
Metabolically healthy obese 18 5381.8 3.3 2.68 1.57–4.56 3.03 1.77–5.19 2.92 1.71–5.01
Metabolically unhealthy obese 75 16,227.8 4.6 2.40 1.69–3.40 2.83 1.98–4.03 2.72 1.90–3.89
Abdominal obesity phenotypes
Metabolically healthy non-abdominally obese 47 38,178.8 1.2 Ref Ref Ref
Metabolically unhealthy non-abdominally obese 137 34,896.0 3.9 1.81 1.30–2.54 1.98 1.41–2.76 1.94 1.38–2.72
Metabolically healthy abdominally obese 15 4344.3 3.5 2.07 1.15–3.70 2.28 1.27–4.09 2.18 1.21–3.92
Metabolically unhealthy abdominally obese 85 14,746.1 5.8 2.61 1.82–3.74 3.00 2.08–4.32 2.89 2.00–4.17
Page 11 of 15Michalsen et al. BMC Cardiovasc Disord          (2021) 21:510  
categories has been pointed out as a potential cause 
of obesity paradoxes [34]. We also show that when the 
analyses were restricted to non-smokers, most estimates 
increased, and women with MHO had a HR of approxi-
mately 1.50 for CVD mortality, albeit non-statistically 
significant due to low power. Importantly, in the UK 
Biobank study, all measures of central obesity, including 
waist circumference, and fat mass were positively associ-
ated with CVD mortality in both sexes [33].
A high ABSI seems to be a more consistent predictor 
of mortality in both women and men compared to a high 
BMI or waist circumference irrespective of metabolic 
health status; however, we have not formally compared 
the models. Studies in a US and four European (Sweden, 
Finland, Turkey and UK) cohorts have shown that where 
BMI or waist circumference tend to show curvilinear 
relationships with mortality, a progressively increasing 
ABSI corresponds to an increasing mortality [17, 35]. 
As opposed to BMI and waist circumference, ABSI was 
linearly and positively associated with both all-cause and 
CVD mortality in men. This pattern for ABSI was not 
found in women, perhaps owing to the weak, but existing 
Fig. 3 The functional relationships between mortality (all-cause and 
CVD) and continuous obesity measures (BMI, waist circumference 
and ABSI) with corresponding hazard ratios with 95% confidence 
bands in women. The reference of all curves were metabolically 
healthy women with a BMI of 26.7 kg/m2, a waist circumference of 
79 cm or an ABSI Z-score of −0.32 (median values for metabolically 
healthy women). p Values originates from likelihood ratio tests 
comparing models with/without linear terms/interaction terms. 
The beta coefficient for metabolic health status was statistically 
significant in all models. Estimates are predicted for median values 
of confounders (smoking, leisure-time physical activity, education, 
alcohol consumption). All models were inherently adjusted for age 
by using attained age as the time-scale. The vertical, dotted lines 
represent the nadir of risk. In panel D, the nadir of risk of metabolically 
healthy and unhealthy differ due to a significant interaction (nadir 
lower in unhealthy than healthy). Note that panel B has different 
dimensions on the y-axis than the other panels. ABSI = a body shape 
index, BMI = body mass index, WC = waist circumference
Fig. 4 The functional relationships between mortality (all-cause and 
CVD) and continuous obesity measures (BMI, waist circumference 
and ABSI) with corresponding hazard ratios with 95% confidence 
bands in men. The reference of all curves were metabolically healthy 
men with a BMI of 27.2 kg/m2, a waist circumference of 90 cm or an 
ABSI Z-score of −0.28 (median values for metabolically healthy men). 
P values originates from likelihood ratio tests comparing models 
with/without linear terms/interaction terms. The beta coefficient 
for metabolic health status was statistically significant in all models. 
Estimates are predicted for median values of confounders (smoking, 
leisure-time physical activity, education, alcohol consumption). All 
models were inherently adjusted for age by using attained age as 
the time-scale. The vertical, dotted lines represent the nadir of risk. 
ABSI = a body shape index, BMI = body mass index, WC = waist 
circumference
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correlation with BMI (0.17 in women vs 0.08 in men). 
Ideally, the correlation between ABSI and BMI should be 
null [17], but due to differences in distributions of height, 
weight and waist circumference between the participants 
in the NHANES and the SAMINOR Study, the formula is 
not a perfect fit in the latter. Recently, ABSI was derived 
specifically for the UK Biobank population [36], and in 
the future deriving population-specific formulae may 
avoid bias from correlations with BMI.
In models not controlling for metabolic health, we 
found linear (men) and U-shaped (women) associations 
between ABSI and both all-cause and CVD mortal-
ity (Additional file  1: Figs. S1 and S2). In women, ABSI 
scores above the mean were strongly associated with 
mortality. At the lower end of ABSI, CIs were wide. In a 
recent study using a large European cohort, the ABSI—
mortality relationship also differed by sex [37]. In women, 
the relationship was J-shaped, with positive associations 
only in the higher quintiles, whereas ABSI was positively 
associated with mortality in all quintiles in men. Our 
results show some similarity to these findings. The afore-
mentioned study showed that people with a high ABSI 
had approximately 30% higher mortality compared to 
people with low ABSI, irrespective of BMI category [37]. 
This suggests that ABSI reflects an altered, detrimental 
body shape that is not reflected in BMI. A small study 
found that ABSI and BMI were negatively and positively, 
respectively, associated with fat free mass, or lean mass, 
indicating that a high ABSI is a good marker of sarco-
penic obesity [38]. In future studies, it may be interesting 
to replace BMI with ABSI in defining categorical obesity 
phenotypes, i.e., to define a MHO phenotype from body 
shape.
Collider bias has been suggested to explain the “obesity 
paradox”: obesity increases mortality and causes cardio-
metabolic disease, but within strata of cardiometabolic 
disease, obesity is not associated with mortality or even 
appears protective in some studies [39, 40], as is seen in 
models with BMI and waist circumference for women 
in this study. The collider bias is a type of selection bias, 
that can be introduced through restriction, regression 
adjustment or stratification on a variable (in this case car-
diometabolic status) that is both affected by the exposure 
(obesity) and share common causes (e.g. genes) with the 
outcome (death). However, the magnitude and direction 
of the bias may be difficult to predict, and some suggest 
it only a partial explanation of the obesity paradox [41].
Izumida et  al. defined metabolically healthy as hav-
ing no MetS components, compared to our defini-
tion of two or fewer components. Hence, metabolically 
healthy people in our study may have been in a transi-
tion phase towards full MetS and converted to metaboli-
cally unhealthy during the study period. Approximately 
50% of people with MHO transition to MUO [4]. A 
study with six repeated measures during 30  years of 
follow-up showed that duration with MHO was longer 
in women than in men. Women transitioned back and 
forth between a healthy and an unhealthy metabolic sta-
tus while maintaining their obesity status, whereas men 
with MHO tended to just transition once from a healthy 
to an unhealthy metabolic status [42]. Nevertheless, in a 
large U.S. cohort of women (N≈90,000), both those with 
MHO at baseline and those with persistent MHO status 
over a period of 24 years were at increased risk of CVD 
compared with the MHNO [43]. Hence, even if women 
spend a longer time in the MHO state before transition-
ing to MUO than men, MHO may not be a benign state 
in a perspective of several decades.
Furthermore, in a study with repeated measures, peo-
ple with MHO had higher all-cause mortality only when 
compared to people with stable MHNO status identified 
during several assessments, and not in comparison to 
the larger group that were MHNO at baseline [44]. This 
serves as a reminder that exposure status in the reference 
group can change over time and a single measurement at 
baseline may give biased results. The implications for this 
study is that the strength of associations may have been 
under-estimated.
In summary, collider bias, residual confounding by 
smoking and misclassification may have distorted some 
of the relationships between obesity and mortality that 
we observed. The pathways linking obesity, metabolic 
health and mortality is complex and dynamic, making it 
a challenge to study using only data measured at a sin-
gle point in time. Although obesity is heterogeneous in 
presentation, it is unlikely a healthy state over time, as is 
evident particularly for the men in our study.
Strengths and limitations
Strengths of the study include the population-based 
nature of the study, the long follow-up time and stand-
ardised measurements of clinical and biochemical 
variables by trained personnel. Linkage to the high 
quality Norwegian Cause of Death Registry enabled 
virtually complete follow-up of total and CVD deaths. 
We included important confounders, such as physi-
cal activity, smoking, alcohol and education. However, 
we did not have information on occupational physical 
activity, which may comprise a large part of the total 
physical activity level throughout the day. Therefore, 
some residual confounding from physical activity may 
be present. Further limitations include non-fasting 
blood samples, and a modest participation rate that 
may have resulted in ‘healthy participation’ bias. There 
are no valid cut-offs for random glucose regarding pre-
diabetes or impaired glucose tolerance. Non-fasting 
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triglycerides reflect increases over fasting values by a 
maximum of 0.3  mmol/L [45]. Inclusion of inflamma-
tion markers (e.g. C-reactive protein) and information 
on non-alcoholic fatty liver disease may have enabled 
us to categorise more precisely into metabolically 
healthy vs unhealthy.
Conclusion
Metabolically unhealthy people have increased risks 
of 15-year all-cause and CVD mortality irrespective of 
obesity status compared to people who were metaboli-
cally healthy at baseline. Associations between BMI, 
waist circumference or ABSI and CVD mortality dif-
fered between the sexes, with strong, positive associa-
tions in both metabolically healthy and unhealthy men. 
The relationship between metabolic risk factors and 
adipose tissue is dynamic and continuous; therefore, 
efforts should continue to be made to reduce obesity 
and metabolic abnormalities across the population.
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(smoking, leisure-time physical activity, education, alcohol consumption). 
All models were inherently adjusted for age by using attained age as the 
time-scale. The vertical, dotted lines represent the nadir of risk. ABSI = a 
body shape index, BMI = body mass index, WC = waist circumference.
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